Advertisement
U.S. markets close in 49 minutes
  • S&P 500

    5,259.27
    +10.78 (+0.21%)
     
  • Dow 30

    39,819.09
    +59.01 (+0.15%)
     
  • Nasdaq

    16,398.48
    -1.04 (-0.01%)
     
  • Russell 2000

    2,123.67
    +9.33 (+0.44%)
     
  • Crude Oil

    83.05
    +1.70 (+2.09%)
     
  • Gold

    2,240.90
    +28.20 (+1.27%)
     
  • Silver

    24.96
    +0.21 (+0.84%)
     
  • EUR/USD

    1.0791
    -0.0039 (-0.36%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2623
    -0.0015 (-0.12%)
     
  • USD/JPY

    151.4070
    +0.1610 (+0.11%)
     
  • Bitcoin USD

    70,673.62
    +1,986.58 (+2.89%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Abercrombie Registers Record Sales in Black Friday Week

Abercrombie & Fitch Co. ANF accomplished record revenues in the United States in the Black Friday week, including the period ranging from Tuesday before Thanksgiving through Cyber Monday. Following the outcome, the company reiterated its fourth-quarter fiscal 2019 view.

Moreover, the company’s Hollister brand performed outstandingly and set a new record in the holiday period. Meanwhile, its flagship brand continued to experience momentum and generated strongest top line over the five years. Further, management cited that Abercrombie’s comparable sales (comps) will outpace the Hollister’s, while the metric at the United States will outperform the international during fiscal fourth quarter.

Following the aforesaid news, shares of the apparel and other accessories retailer jumped about 4% during the trading session on Jan 13. In the past three months, Abercrombie’s shares have increased 18.8% compared with the industry’s 6.9% rise.


The Zacks Rank #3 (Hold) company is making significant progress in expanding its digital and omni-channel capabilities. Further, the company is progressing well on its goal of delivering integrated digital and in-store shopping experiences. Management is also committed to smoothly execute its transformation initiatives. Some of the latest actions include the launch of expanded payment options in the United States, a partnership with Klarna, the introduction of its China loyalty program in stores and on Tmall, the rebranding of the Abercrombie loyalty program, as well as offering Instagram checkout.

With that said, we expect these initiatives to contribute to Abercrombie’s top and bottom line in fiscal fourth quarter.

For now, the company continues to anticipate fiscal fourth-quarter net sales in the range of flat to up 2% from the prior-year quarter’s figure. This includes an adverse impact of nearly $5 million from negative currency translations. Meanwhile, it still projects comps to be flat to up 2%.

The company continues to expect gross margin contraction of 150 basis points (bps) from the year-ago quarter’s reported level of 59.1%. This will likely include negative impacts of 70 bps from currency and estimated China tariffs.

Further, Abercrombie continues to expect operating expenses (excluding other operating income) in the band of flat to up 2% from adjusted operating expenses of $555 million reported in fourth-quarter fiscal 2018.

Retail Stocks to Watch

Chico's FAS, Inc CHS has an impressive long-term earnings growth rate of 15%. The stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Zumiez Inc ZUMZ, also a Zacks Rank #1 stock, boasts an expected long-term earnings growth rate of 12%.

Tilly's, Inc TLYS has an expected long-term earnings growth rate of 11% and flaunts a Zacks Rank #1.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Zumiez Inc. (ZUMZ) : Free Stock Analysis Report
 
Abercrombie & Fitch Company (ANF) : Free Stock Analysis Report
 
Chico's FAS, Inc. (CHS) : Free Stock Analysis Report
 
Tilly's, Inc. (TLYS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement